Cure TV

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in terms of prostate cancer therapy.

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.

Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

Melissa Ursini, diagnosed with stage 2 colon cancer, shares her journey to raise awareness and encourage early detection through colonoscopies.

Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.

Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.

The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.

There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it.

An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet and increased severe side effects.

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments.

Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a vaccine.

Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.